To access this element change to forms mode OFF
Grant Award View - GA980
Platelet glycoprotein proteolysis: novel mechanisms and risk factors
GA ID:
GA980
Agency:
National Health and Medical Research Council (NHMRC)
Approval Date:
24-Oct-2017
Publish Date:
30-Jan-2018
Category:
Medical Research
Grant Term:
1-Jan-2018 to 31-Dec-2020
Value (AUD):
$441,473.49
(GST inclusive where applicable)
One-off/Ad hoc:
No
Aggregate Grant Award:
No
PBS Program Name:
NHMRC 16/17 1.1 Health and Medical Research
Grant Program:
Project
Grant Activity:
Platelet glycoprotein proteolysis: novel mechanisms and risk factors
Purpose:
Platelets are the richest source of amyloid precursor protein (APP) in the body. Platelet ADAM10 regulates both the expression and function of the major platelet collagen receptor GPVI, and protective APP processing. Coagulation protein Factor X has a role in activation of ADAM10. This activation is disrupted in blood that has been treated with direct oral anticoagulant (DOAC) rivaroxaban. This grant will investigate the implications for people taking rivaroxaban on regulation of APP and GPVI.
Internal Reference ID:
GNT1147214
Selection Process:
Targeted or Restricted Competitive
Confidentiality - Contract:
Yes
Confidentiality Reason(s) - Contract:
Privacy Act 1988
Intellectual property
Intellectual property
Confidentiality - Outputs:
Yes
Confidentiality Reason(s) - Outputs:
Intellectual property
Grant Recipient Details
Recipient Name:
Australian National University
Recipient ABN:
52 234 063 906
Grant Recipient Location
Suburb:
Canberra City
Town/City:
Canberra City
Postcode:
2601
State/Territory:
ACT
Country:
AUSTRALIA
Grant Delivery Location
State/Territory:
ACT, WA
Postcode:
Multiple
Country:
AUSTRALIA